Blood tests before & during GLP-1 treatment: the India guide.

Why do blood tests matter before a GLP-1 injection?

These are not appetite-suppressant supplements. They act on multiple organ systems at once — the pancreas, kidneys, thyroid, liver, gallbladder and gut — and they powerfully change how much you eat. For scale: in the STEP-1 trial (Wilding et al., NEJM, 2021; N=1,961), semaglutide produced a mean body-weight change of −14.9% at 68 weeks versus −2.4% on placebo; in SURMOUNT-1 (Jastreboff et al., NEJM, 2022), tirzepatide produced reductions of −15.0%, −19.5% and −20.9% at the 5/10/15mg doses over 72 weeks.

What India's own guidelines say

The relevant document is the Endocrine Society of India (ESI) Clinical Practice Guidelines for Obesity. The 2025 update set the threshold for drug therapy at BMI >27, or >25 with at least one comorbidity — lower than Western cut-offs, because Asian-Indians carry more visceral fat at any given weight. The ESI baseline work-up includes fasting and post-prandial glucose, HbA1c, creatinine, fasting lipid profile, TSH, LFTs, serum electrolytes, uric acid and an assessment of the cortisol axis. It tells doctors to clinically rule out gastroparesis and gallbladder disease first, makes contraception mandatory for women of childbearing age, advises review monthly for three months then quarterly, and considers a drug stoppable if it fails to produce a 5% body-weight reduction. Notably, Indian guidelines do not explicitly list CBC, B12 or vitamin D as mandatory — but we recommend them anyway, and so do most practising Indian doctors, because deficiency is near-universal here.

The baseline panel: every marker, in plain language

Blood sugar markers

• HbA1c (glycated haemoglobin): your average blood sugar over the past 2–3 months. The single most important baseline marker — it confirms prediabetes or diabetes, guides drug choice, and becomes your benchmark for improvement. No fasting required.
• Fasting blood glucose: a snapshot of your sugar after an overnight fast, read together with HbA1c.
• Fasting insulin + HOMA-IR (optional but valuable): fasting insulin shows how hard your pancreas is working. HOMA-IR — (fasting insulin × fasting glucose) ÷ 405, from Matthews et al., Oxford, 1985 — estimates insulin resistance, often years before sugar rises into the diabetic range. Above roughly 1.9–2.5 suggests insulin resistance in many populations (cut-offs vary by lab). Especially relevant for the Indian thin-fat phenotype.

Organ-function markers

• Liver function test (LFT): enzymes (ALT/SGPT, AST/SGOT), bilirubin and proteins. Many people with obesity have fatty liver (MASLD); GLP-1s often improve it, so a baseline shows where you started.
• Kidney function (KFT) / creatinine + eGFR: if GLP-1 side effects (vomiting, diarrhoea) cause dehydration, kidneys can be stressed — acute kidney injury has been reported. No dose change is needed for kidney impairment, but a baseline matters.
• Serum electrolytes (sodium, potassium): a baseline so that significant vomiting or diarrhoea can be checked for dangerous shifts.
• Uric acid: commonly elevated in metabolic obesity; part of the ESI baseline.

Thyroid and blood count

• TSH: screens for hypothyroidism — a common, treatable cause of weight gain and fatigue that should be caught before assuming a drug isn't "working."
• CBC (haemogram): flags anaemia; a high MCV (large red cells) can be an early hint of B12 deficiency.

The two markers that matter most in India

• Vitamin B12 (cobalamin): essential for nerves and red-blood-cell formation. India's largely vegetarian diet makes deficiency common — and GLP-1s reduce intake further.
• Vitamin D (25-OH): critical for bone, muscle and immune function. Deficiency is the norm in India, and low vitamin D can worsen the muscle-function loss that accompanies rapid weight loss.

Screened by history, not always by blood

• Amylase / lipase: not a routine FDA-label baseline, but many doctors check them given the rare pancreatitis risk. Note: per the Mounjaro prescribing information, tirzepatide raises mean amylase by 33–38% and lipase by 31–42% even without pancreatitis, so these are interpreted with care.
• Calcitonin: not a routine screen — the labels say routine calcitonin or thyroid ultrasound is of uncertain value due to low specificity. Relevant only with an MTC/MEN-2 history (where the drug is contraindicated entirely); a calcitonin above 50 ng/L would prompt specialist evaluation.
• Pregnancy test: GLP-1s are not recommended in pregnancy; screened in women of childbearing age.

Why do B12 and D3 deserve special attention in India?

B12 deficiency is endemic. Singla et al. (Indian Journal of Endocrinology and Metabolism, 2019) found a 47% prevalence in general adults (B12 <200 pg/ml). A large adolescent study (Chakraborty et al., JHND, 2018; N=2,403) found 32.4% deficient overall — and 51.2% of obese adolescents. The reasons are structural: a predominantly vegetarian diet (B12 comes mainly from animal foods) plus high rates of metformin use.

Vitamin D deficiency is even more widespread. Studies put prevalence at 70–90% (Ritu & Gupta, Nutrients, 2014). A 2025 Metropolis Healthcare analysis of over 22 lakh tests found 46.5% deficient and a further 26% insufficient — roughly three in four Indians below optimal — with South India highest at 51.6% and teenagers highest at 66.9%.

There's a second, specific reason to watch B12: many Indian GLP-1 users are also on metformin. The ADA's Standards of Care (2025/2026) recommends periodic B12 assessment on long-term metformin, because it reduces B12 absorption. Stack that on India's baseline deficiency and a GLP-1's appetite suppression, and B12 monitoring becomes essential, not optional. The practical takeaway: check B12 and D3 at baseline, and if low, supplement before or alongside starting — don't wait for symptoms. Because vegetarian diets are doubly affected, our vegetarian protein guide covers how to eat around these gaps.

Monitoring during treatment: what to repeat and when

Muscle mass and protein — the under-discussed issue

Any rapid weight loss costs some lean (muscle) mass. In an analysis in Circulation (Prado et al., 2024), about 45.5% of weight lost on semaglutide in STEP-1 was lean mass, and about 34.3% on tirzepatide in SURMOUNT-1. Endocrine Society research at ENDO 2025 found that being older, female, or eating less protein predicted greater muscle loss. Blood tests don't measure muscle directly, but the practical defence is adequate protein plus resistance training — both harder when appetite is suppressed. Our muscle-protection guide covers the full protocol.

Gallbladder and pancreas

GLP-1s raise gallbladder-disease risk — a meta-analysis of 76 trials (He et al., JAMA Internal Medicine, 2022; 103,371 patients) found a relative risk of 1.37 for gallbladder or biliary disease, rising to RR 2.29 in weight-loss trials specifically. This isn't caught by routine blood tests; watch for persistent right-upper-abdominal pain, fever or jaundice and get an ultrasound if they appear. Same logic for pancreatitis: severe, persistent pain radiating to the back warrants stopping the drug and checking lipase.

Red flags: when results delay or stop GLP-1 therapy

During treatment, act on: signs of pancreatitis (stop and test lipase), gallbladder symptoms (ultrasound), dropping B12 (supplement), worsening kidney function with vomiting (rehydrate, recheck), or failure to lose ≥5% body weight by about 3 months (reassess the drug).

Kaivo's panels vs. the typical handwritten prescription

Most Indian doctors, pressed for time, write "HbA1c, CBC, B12, D3." That covers the basics but misses kidney, liver, thyroid and lipid baselines. Kaivo's panels are designed around the full GLP-1 work-up.

Which should you choose? The 12-Marker Essential is right for most healthy adults starting a GLP-1. The 35-Marker Comprehensive is worth it if you have diabetes, PCOS, fatty liver, are on metformin, are vegetarian/vegan, or simply want the fullest picture. Both are dramatically cheaper than ordering tests individually: bought piecemeal, an HbA1c runs roughly ₹199–₹360, a lipid profile ₹497–₹800, and a vitamin D test about ₹1,500 — so a full work-up can cross ₹3,000–₹4,000. A bundled panel is far more economical, much like comparing options on our GLP-1 cost calculator before you commit.

The bottom line

A GLP-1 is a powerful, organ-spanning medication — not a casual weight-loss shortcut. A proper baseline panel keeps you safe, confirms the drug is right for you, and lets you watch your metabolic health improve. In India the case is even stronger: rampant B12 and vitamin D deficiency mean an appetite-suppressing drug can quietly worsen nutrition unless you measure and supplement. Get the baseline, repeat the key markers every few months, and treat B12/D3 as core, not optional.

1. Wilding JPH et al. STEP-1. New England Journal of Medicine 2021.
2. Jastreboff AM et al. SURMOUNT-1. New England Journal of Medicine 2022.
3. Madhu SV, Kapoor N, Das S, Raizada N, Kalra S. ESI Clinical Practice Guidelines for Obesity in India (2022; 2025 update). Indian Journal of Endocrinology and Metabolism.
4. Singla R et al. Vitamin B12 Deficiency is Endemic in Indian Population. Indian Journal of Endocrinology and Metabolism 2019.
5. Ritu G, Gupta A. Vitamin D deficiency in India. Nutrients 2014. Metropolis Healthcare nationwide vitamin D analysis, 2025.
6. He L et al. GLP-1 RA and gallbladder/biliary disease, meta-analysis. JAMA Internal Medicine 2022.
7. Prado CM et al. Lean-mass loss with semaglutide and tirzepatide. Circulation 2024. ADA Standards of Care in Diabetes 2025/2026.